{"id":"lansoprazole-marketed-approved-dose","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Headache"},{"rate":"8-10%","effect":"Diarrhea"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"4-6%","effect":"Nausea"},{"rate":"3-5%","effect":"Constipation"},{"rate":null,"effect":"Vitamin B12 deficiency (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL480","moleculeType":"Small molecule","molecularWeight":"369.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.","oneSentence":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:18.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Acid-related dyspepsia"}]},"trialDetails":[{"nctId":"NCT07313774","phase":"PHASE3","title":"A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)","status":"NOT_YET_RECRUITING","sponsor":"Cinclus Pharma Holding AB","startDate":"2026-03","conditions":"GERD (Gastroesophageal Reflux Disease)","enrollment":1050}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lansoprazole - Marketed approved dose","genericName":"Lansoprazole - Marketed approved dose","companyName":"Cinclus Pharma Holding AB","companyId":"cinclus-pharma-holding-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}